Bone-Modifying Agent

9 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.

Connect With Us

+63 919 076 9100

Bone-Modifying Agent (9)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Clear all filters

Molecule	Drug Class / Mechanism	Oncology Type	Inquiry
Denosumab	RANKL Inhibitor	Both (Solid & Hematologic)
Molecule Denosumab Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism RANKL Inhibitor
Alendronate (Onc Adjacent)	Bisphosphonate	Both (Solid & Hematologic)
Molecule Alendronate (Onc Adjacent) Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Clodronate Disodium	Bisphosphonate	Both (Solid & Hematologic)
Molecule Clodronate Disodium Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Etidronate	Bisphosphonate	Both (Solid & Hematologic)
Molecule Etidronate Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Ibandronate Sodium	Bisphosphonate	Both (Solid & Hematologic)
Molecule Ibandronate Sodium Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Pamidronate Disodium	Bisphosphonate	Both (Solid & Hematologic)
Molecule Pamidronate Disodium Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Risedronate (Onc Adjacent)	Bisphosphonate	Both (Solid & Hematologic)
Molecule Risedronate (Onc Adjacent) Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Romosozumab (Onc-Adjacent Bone)	RANKL Inhibitor	Both (Solid & Hematologic)
Molecule Romosozumab (Onc-Adjacent Bone) Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism RANKL Inhibitor
Zoledronic Acid	Bisphosphonate	Both (Solid & Hematologic)
Molecule Zoledronic Acid Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate

Denosumab Bone-Modifying Agent
Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism RANKL Inhibitor
Alendronate (Onc Adjacent) Bone-Modifying Agent
Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Clodronate Disodium Bone-Modifying Agent
Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Etidronate Bone-Modifying Agent
Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Ibandronate Sodium Bone-Modifying Agent
Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Pamidronate Disodium Bone-Modifying Agent
Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Risedronate (Onc Adjacent) Bone-Modifying Agent
Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate
Romosozumab (Onc-Adjacent Bone) Bone-Modifying Agent
Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism RANKL Inhibitor
Zoledronic Acid Bone-Modifying Agent
Therapeutic Category Bone-Modifying Agent Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Bisphosphonate